News

While it is too soon to tell, this research involving broadly neutralizing antibodies could point to new methods for preventing vertical transmission.

Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.

New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.

Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.

Switching HIV treatment regimens during the first trimester; drivers of viral breakthrough during pregnancy; HIV’s effect on liver risk after hepatitis C treatment; hepatic steatosis among young people with HIV.

Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

Traditional factors vs. HIV-specific factors in non-communicable complications; frailty and fracture risk among women; lipid measurements and coronary risks; new data on efavirenz and birth defects.

E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.

The impact of stigma on cognitive performance; risk factor dissonance among young black MSM; pregnancy and the HIV care continuum; new data on pediatric raltegravir use.